84 results about "Novel protein" patented technology

This invention discloses a milk protein containing composition comprising: at least one milk protein; at least a first protein; at least a second protein; and at least a linker comprising an amino acid sequence coded by nucleotide sequence which is at least 80% similar to sequences selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21

The present invention relates to modified Dda helicases which can be used to control the movement of analytes such as polynucleotides. The modified Dda helicases are used in analyte detection and characterisation. The present invention also relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore.

A target protein drug binding prediction method based on meta learning and subgraph matching, by constructing protein structure, drug small molecule structure and its binding energy value, the meta learning training task is established according to protein grouping, that is, as the main model of the meta model; the sub model and its loss function for the protein prediction task are obtained after fine tuning of the meta model; then the task self-adaptive self-attention model is established to balance the optimization contribution of the sub model of each protein prediction task to the meta model, the weighted average is used for the loss function of the sub model of each protein prediction task to obtain the meta model loss function; then the meta model loss function is used to calculate the gradient, the meta model parameters are updated and optimized based on the preset learning rate, and after the training is completed, the trained meta model is used for fine tuning of the test set of new protein samples, the prediction sub model of the new protein is obtained, the sub model is used for prediction of the protein test set, and the evaluation result is obtained. The training method combining meta learning and subgraph matching can effectively avoid shortcut learning, enhance the generalization effect, and also solve the problem that the previous prediction model is difficult to predict the newly discovered protein.

The application discloses a novel protein separator capable of purifying water quality through bacteria and algae culture and automatically maintaining dynamic balance, which comprises a casing, a gas-water generating device connected to the bottom of the casing, a separation component and a bacteria and algae culture part located above the water level in the casing, a sewage outlet located above the separation component in the upper part of the casing, a water outlet in the lower part of the casing, the separation component comprising a conical pipe and a straight pipe connected in series, the inner diameter of the conical pipe gradually increasing from bottom to top, the lower end of the straight pipe being connected with the upper end of the conical pipe, the separation component having one or more vertical notches, and the upper end of the notch extending to the upper end of the straight pipe. The separation component is used for repeatedly enriching, concentrating and dewatering the pollutants, and the dynamic balance of the bacteria and algae in the equipment and the water body to be treated is realized through the bacteria and algae culture part, so that the volume of the separated pollutants can be greatly reduced, the concentration of the separated pollutants can be improved, and the separated pollutants can be utilized, which has positive significance for reducing the treatment cost of the pollutants and recycling the pollutants.

The present application provides a novel protein or polynucleotide variant, a Corynebacterium glutamicum strain containing the protein or polynucleotide variant, and a method for producing L-lysine using the strain.

The present invention relates to novel protein arginine methyltransferase 5 (PRMT5) inhibitor compounds and methods for treating adenomatous polyposis coli (APC) loss-of-function driven adenoma diseases in a human in need thereof.

The invention discloses a novel protein structure prediction method based on AI, and particularly relates to the technical field of protein structure research, a protein amino acid sequence is converted into a multi-dimensional feature matrix, homologous fragment information is fused, and feature representation with physical and chemical properties and potential folding rules is obtained; extracting local residue relation and global sequence dependency information by combining graph convolution and a self-attention mechanism, constructing a multi-scale subsurface space, and realizing comprehensive description of a folding trend; candidate conformation generation and uncertainty indexes are introduced into the submerged space, and it is ensured that the prediction process has reliable quantization; ranking and screening the priorities of the candidate conformations in combination with an energy constraint function and structural similarity measurement, and outputting an optimized structure set with reasonable energy and coordinated trend; a prediction structure is generated through multi-modal information fusion, and credibility evaluation is performed, so that the problem that prediction accuracy and interpretability are difficult to consider at the same time in an existing method is effectively solved.

The present disclosure is generally related to recombinant microbial cells expressing heterologous proteins of interest. Certain aspects of the disclosure are therefore related to, inter alia, recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the instant disclosure are particularly suitable for use in the expression, production and secretion of heterologous proteins.

The invention discloses a SpaD-based polypeptide-protein reaction pair, and belongs to the technical field of protein engineering. The D2-D3 structural domain of the corynebacterium diphtheriae pilus protein SpaD is split into reaction pairs in two modes, the two parts can be efficiently recombined and react to generate isopeptide bonds, and covalent coupling is achieved. Wherein when the D2 structural domain is split into reaction pairs, a D214-T455 residue of an original sequence is a capturer protein (D2C), and an E182-K213 residue of the original sequence is a tag polypeptide (D2T); when the D3 structural domain is split into reaction pairs, the E182-D434 residue of the original sequence is a capturer protein (D3C), and the G438-T455 residue of the original sequence is a tag polypeptide (D3T). The reactivity of a reaction pair obtained by splitting D3 is equivalent to that of a common spy reaction pair, is not influenced by the position of a tag sequence, is orthogonal to the spy reaction pair and a probe reaction pair, is a novel protein coupling tool, and has a relatively high practical value in protein engineering.

The present disclosure relates generally to recombinant microbial cells expressing heterologous proteins of interest. Accordingly, certain aspects of the present disclosure relate, inter alia, to recombinant Bacillus cells having enhanced protein production capabilities, novel protein signal sequences, recombinant polynucleotides encoding heterologous proteins of interest, and related compositions and / or methods thereof. Thus, as exemplified herein, the recombinant Bacillus cells of the present disclosure are particularly suitable for use in the expression, production, and secretion of heterologous proteins.

Provided are methods for treating cancer by administrating to an individual who has the cancer an inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD) and an immune checkpoint inhibitor. Also provided are methods for promoting translation of proteins within cells such that proteins include one or more misincorporated amino acids to thereby develop new proteins that contain neoantigens. Vaccines that include the neoantigens are included. Methods for producing and detecting misincorporation of a tyrosine in proteins expressed by cells are also provided.

Provided are a novel protein having histidine exporting activity. an L-histidine producing microorganism modified to express the protein. and a L-histidine producing method using the microorganism.

The application relates to a protein characterization learning method and device, computer equipment and a storage medium. The method comprises the following steps: collecting protein sequence, structure and function annotation information, and constructing a multi-modal feature data set; performing multi-modal feature extraction on the multi-modal feature data set by using a MASSA framework to obtain protein multi-modal representation; constructing a graph network by using the protein multi-modal representation, and storing the representation and a historical model of an existing protein task in the graph network; in the training process of a new protein task, a memory enhancement mechanism is used to retrieve a similar node of the new protein task from the graph network, a historical model of an existing protein task corresponding to the similar node is obtained, model parameters of the historical model are transferred by using a transfer learning framework, and model training is performed on the new protein task. The application effectively alleviates the data scarcity problem and improves the accuracy and generalization ability of the model in a small sample learning task.

Disclosed are a protein degrader targeting O-GlcNAc Transferase (OGT), and a preparation method therefor and a use thereof. The inventors of the present invention have creatively discovered that a compound recruits MDM2 by means of its interaction with nucleolin (NCL), and through further experiments have found that it can serve as a novel recruiting element for MDM2, which can be used in the preparation of targeted protein degraders and other applications. Using the above findings, the inventors have prepared a novel protein degrader compound targeting OGT, and have found through experimentation that the prepared targeted protein degrader can effectively induce the degradation of OGT, for use in the treatment of diseases mediated by OGT or associated with O-GlcNAc glycosylation (such as neurodegenerative diseases, obesity, tumors, diabetes and complications thereof, cardiovascular diseases, etc.), and will have very promising application prospects in the fields of medicine and health management.

To provide a new serum marker whose expression is restricted to the latent form of toxoplasmosis (bradyzoites / cysts). Also provided is an antibody that specifically binds to the new protein.SOLUTION: The present invention relates to a new Toxoplasma gondii protein, hereinafter referred to as BCLA, a new serum marker whose expression is restricted to the latent form of toxoplasmosis. This specific protein and its antigenic fragments can be used to detect autoantibodies in the serum of patients for the diagnosis of latent forms of toxoplasmosis. The invention also relates to derived antibodies generated by BCLA immunization that specifically bind to this new protein.SELECTED DRAWING: None

The application relates to a cell line stably expressing an orthogonal aminoacyl tRNA synthetase / tRNA pair, a HEK293T cell line capable of stably expressing an EcTyr orthogonal aminoacyl tRNA synthetase / BsTyr tRNA pair is constructed, and a construction method of the cell line is disclosed. The construction method is to stably integrate the orthogonal EcTyr aminoacyl tRNA synthetase and BsTyr tRNA genes into the HEK293T cell genome by means of a PiggyBac transposon system and plasmid stable transfection. The constructed cell line genome is integrated with the EcTyr orthogonal aminoacyl tRNA synthetase and BsTyr tRNA genes, and provides a stable platform for efficiently introducing unnatural amino acids at any site of a protein. The application has the effects of further laying an experimental foundation for the exploration of novel protein structures and functions and the research and development of protein drugs containing certain specific functions.

The present application has an object to provide a novel protein cross-linking method. By allowing both an oxidoreductase such as laccase and a protein deamidase such as protein glutaminase to act on a substrate protein, a cross-linking reaction is promoted.

The application relates to the technical field of the cross of protein engineering and computational biology, and discloses a uracil-DNA glycosylase de novo design method based on physical priori and deep learning. A fixed function motif containing a catalytic core layer, a DNA binding interface layer and a structural support layer is extracted, and the fixed function motif and a substrate analog are used as geometric constraints; a full-atom diffusion model is used to generate a new protein topological skeleton; iteration optimization is carried out through deep learning sequence generation and physical force field refinement; sub-Angstrom level precision control of an active pocket and sequence-structure self-consistency are realized; finally, multi-dimensional screening is carried out by using an orthogonal prediction model and a Pareto optimal strategy. The application can break through the natural evolution limit, obtain a de novo designed UNG which is unique in sequence, has a sub-Angstrom level precision catalytic pocket and is compact in structure, and provide a new computational design strategy for the development of programmable gene editing tool enzymes.

A truncated σ1 protein or a variant thereof, a fusion protein and trimeric protein containing the truncated σ1 protein or the variant thereof, and a nucleic acid molecule and vector containing a nucleotide sequence encoding the truncated σ1 protein. The present invention further relates to a vaccine, kit and pharmaceutical composition containing the truncated σ1 protein or the variant thereof, the trimeric protein, the nucleic acid molecule or the vector.

The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins. The novel proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.

The present application relates to a kind of novel protein that is specifically combined with small molecule DFHBI and induces its fluorescence enhancement and application thereof.The amino acid sequence of the protein is shown as SEQ ID NO:1.Experimental results show that, after being combined with the protein of the present application, the fluorescence signal of DFHBI is significantly enhanced compared with the free state, and a low-background, high-signal-to-noise ratio fluorescence response system can be formed.

The invention belongs to the technical field of molecular diagnosis, and particularly relates to application of a protein marker Vincin related to cancer-related fatigue. According to the application, a novel protein marker Vincin related to cancer-related fatigue is found, so that a novel target spot is provided for diagnosis, evaluation and targeted intervention of cancer-related fatigue, and a corresponding detection reagent can be used for developing a kit for diagnosing and / or evaluating cancer-related fatigue; a substance for inhibiting the expression or activity of the compound can be used for developing a medicine for preventing and / or treating cancer-related fatigue, and has a good clinical application prospect.

The invention provides a protein sequence structure joint design method based on a natural language, and relates to the technical field of artificial intelligence, and the method comprises the following steps: constructing natural language information representing protein functions, an amino acid secondary structure and an amino acid contact diagram according to protein design requirements; processing the natural language information through a text encoder to generate condition features; meanwhile, the triangular perception encoder is used for processing the amino acid secondary structure and the amino acid contact diagram information, and condition features are generated; a protein map structure is constructed through multiple pieces of modal information, and local and global context features of protein are captured; iteratively updating the amino acid sequence and three-dimensional structure coordinates of the protein by using an equivariant decoder; according to the method, invariant cross entropy loss, invariant frame alignment loss and contrast loss are utilized to perform joint optimization on generation of protein sequences and structures, and after multiple rounds of iteration, protein amino acid sequences and three-dimensional structures with'sequence-structure-function 'consistency are output.

The present invention relates to a novel protein production system composed of a non-spore-forming bacterial strain of the genus Bacillus transformed with a plasmid containing an expression cassette for a protein of interest controlled by a strong, stationary-phase promoter. The proteins of interest thus produced are present in a bacterial sac or anchored to the surface of the bacterium.

A multimodal generative model of protein families is provided to jointly model the sequences and structures of proteins within a protein family. The model is used for controllable protein generation and representation learning. The model leverages in¬ context learning to infer underlying evolutionary constraints that give rise to the family's characteristic sequence features, structural architectures, and / or functional properties. These inferred evolutionary constraints, coupled with a flexible grammar for specifying explicit sequence and structural constraints, enables the controlled generation of novel family members, including variants with optimized or enhanced characteristics relevant to their function. The model is as an encoder-decoder transformer, preferably one encoder, and two decoders. The encoder processes a user-provided prompt comprising a set of proteins and that guides the two decoders toward generating novel proteins with desired characteristics.

The present invention relates to novel protein pores and their use in analyte detection and characterization. In particular, the invention relates to an isolated pore complex formed from a CsgG-like pore and a modified CsgF peptide, or homolog or mutant thereof, thereby incorporating an additional channel constriction or read head in the nanopore. The invention also relates to a transmembrane pore complex and a method for producing said pore complex, and their use in molecular sensing and nucleic acid sequencing applications.

The present disclosure provides novel protein isoforms, including transmembrane proteins, encoded by variant transcripts generated from non-canonical splicing, and corresponding peptides, nucleic acids, vaccines, antibodies and immune cells that can be used in diagnosis and therapy.

The invention relates to the technical field of protein engineering, in particular to a nano antibody NbA and epitope AYD interaction system for plant cell research, a biosensor and a nano antibody and epitope interaction system, which comprise a first carrier and a second carrier, the first carrier contains a nano antibody NbA; the second carrier contains an epitope AYD; the gene sequence of the nano antibody NbA is as shown in SEQ ID NO: 1, and the gene sequence of the epitope AYD is as shown in SEQ ID NO: 2. The nano antibody NbA and the epitope AYD are applied to plant cells for the first time, and a novel protein-protein interaction tool and a high-specificity protein tag are provided for future research in the plant field on the basis that original molecular solubility and biophysical characteristics are not affected. Specific binding of the nano antibody NbA and the epitope AYD of the gene sequence in plant cells is realized, and a research basis is provided for researching other frontier problems in the plant field in the future.

The present invention provides an Fc binding polypeptide having improved base stability, comprising a mutant of the B domain of Protein A. Also provided are a multimer comprising a polypeptide, a separation matrix comprising a polypeptide or multimer, and a method of separating a protein comprising Fc. The polymer or the separation matrix containing the polypeptide has obviously improved alkaline stability and improved binding capacity with IgG in the alkali cleaning process.

The invention discloses a TYK2-targeted protein degradation agent as well as a preparation method and application thereof. The inventor creatively discovers that the compound recruits E3 ubiquitin ligase MDM2 through interaction with NCL, and further experiments discover that the compound can be used as a novel recruitment element of the MDM2 to be used in the aspects of preparation of a targeted protein degradation agent and the like. The inventor prepares a novel TYK2-targeting protein degradation agent compound by utilizing the discovery, and experiments find that the prepared TYK2-targeting protein degradation agent can effectively induce degradation of TYK2, is used for treating TYK2-mediated diseases (such as autoimmune diseases and inflammatory diseases), and has a very good application prospect in the field of medicines.